Latest Breast International Group Stories
While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored.
Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.
EAST HANOVER, N.J., Aug.
- Femara showed reduced risk of death by 13% (P=0.08), despite inclusion of patients crossing over from tamoxifen to Femara therapy - In a separate censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was 19% - Long-term follow-up from major independent BIG 1-98 trial reinforces starting with Femara as the optimal treatment strategy versus tamoxifen EAST HANOVER, N.J., Dec.
- To swell, as grain or wood with water.